1 minute reading time (120 words)

FDA Approves Abbott's "Low Dose," Recharge-Free Spinal Cord Stimulation System with up to Ten Year Battery Life for People Living with Chronic Pain

Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Proclaim XR™ recharge-free neurostimulation system for people living with chronic pain. The Proclaim XR platform offers a low dose of Abbott's proprietary BurstDR™ stimulation waveform, which was created based on scientific insights from doctors and research to mimic natural patterns found in the brain. It works by using low doses of mild electrical pulses to change pain signals as they travel from the spinal cord to the brain. The delivery of lower doses of spinal cord stimulation (SCS) helps extend the system's battery life, allowing people to experience pain relief, without the hassle of recharging, for up to 10 years*. Full story

Related Posts

Want more pain resources? Check out our library of on-demand education, upcoming events, and more.

Learn More